HUE026026T2 - Új, C-met-dimerizációt gátló ellenanyagok és alkalmazásuk - Google Patents

Új, C-met-dimerizációt gátló ellenanyagok és alkalmazásuk Download PDF

Info

Publication number
HUE026026T2
HUE026026T2 HUE08786050A HUE08786050A HUE026026T2 HU E026026 T2 HUE026026 T2 HU E026026T2 HU E08786050 A HUE08786050 A HU E08786050A HU E08786050 A HUE08786050 A HU E08786050A HU E026026 T2 HUE026026 T2 HU E026026T2
Authority
HU
Hungary
Prior art keywords
antibody
met
cdr
human
antibodies
Prior art date
Application number
HUE08786050A
Other languages
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026026(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE026026T2 publication Critical patent/HUE026026T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Claims (8)

  1. tlj, €-MET~»IMEM£ÂCK>T GAfL<1RUHAANYAGOK ÉS; ARlGkLMÂZA&amp;AlK Szabadalmi igénypontok
    1. Izolált ellenanyag vagy egy c-Met-ét káté diyalims fetgmgtise, azííal jölieasexve, hö^'W «llsaaayag rendre SEQ ÏD No 1, 2 és ;| SKsnidNasöisasáyAzekmelit tartalmazó -et, CDR-H2-t és €DR-H3-at tartalmazó ndtézláneoi, és reiidire SEQ !I> Net 10, 11 és 12 szerinti antinosav-szekvenciát lajtaiamé CDR-Ll-ét, CDR -i.3 t és CPR-IQ-at í&amp;riahpszé kónnyPáneot tariaiaíaz,
  2. 2. Az I. igénypont szeristi eiléeímyag vagy Agy cHfet-ei köM divalens Ragrnense, azzal jellétnezve, hogy SBQ ID No. 1 &amp; saéritó! ;üsáaö^iv-as#£v«ró&amp;t' tar&amp;taszó adfe&amp;Üasöiés· SEQ3P fl szerinti mûm-sav-szekvencíát tartalmazó kdrmyűláacoí tartsiœaz.3, Egér hibridóma, amely képes 2, igenypoöí szeriéi sífea·· anyagot szekretaM, azzal jellemezve, hogyä 2082, méretes 14-én a párizsi: GNCM, Esstear Mezeiben í-3731 számért letétbe Irelyezeit egér hibridóma.
  3. 4. .Az 1, vagy 2; igénypont szerinti ellenanyag vagy egy c-Met-el fölé dívalérts frsgmense, azzal jellemezve, begy az ellenanyag monoklonAlls ellenanyag, 5. A 4. igénypont szerinti ellenanyag v® egy e-Meí-et fcdtö dlvaleas ífagmense, azzal jellemezve, kegy m ellenanyag kiírtéra; ellenanyag, ahoi a körtnyüiáne és nehéziánc konstans réglék ember; ellenanyagból származnak.
  4. 6. Az 1-5. igénypontok bármelyike szeristi ellenanyag vagy egy e-Met-et kötő divalens iragmense, azzal jélléatézyëÿ hogy c-Ma-hez; speclik«sás:kStÖárií képes. % A 4 Ig&amp;jyposkszerinti ellenanyag vagy egy e-Met-et kötö divaiens SMgmeme, azzal jeOeaiezve, hogy c-Met ligandfüggö vagy iig&amp;nditiggetlen aktiválását gátolni képes. S, A ?. igénypont szerinti ellenanyag vagy egy c-Metres kötő divaiens feigmersse. azzal jellemezve, hogy gátolja a e-Met dimerizációjáí, ·&amp; Izolált nnkkinsav, azzal jellemezve, hogy a következő nukiatesayak közillválasztott: aj L vagy 2. igénypont szerinti ellenanyagot vagy egy e-Mei~eí feöfö divalens Éagmensét kódoló sakléiasayj DNS vagy RNS, feji a SBQ ÏD No. 24 szerinti CDR-H1 azekvenciái. a SEQ 1D No. 25 szerinti CDR-H2 székvmeiáí«: a SEQ ÎD No. 26 szerinti CDR-H3 szekvenciát és a SEQ tEfNö* 33 szerinti CDR-L1 f W$- Wt- 1%, '$4 szerinti CDR-L2 szekvenciát és a SEQ IDNo. 35 szerinti CDR-L3 szekvenciát tariahnázó QN'S-szekveöeiát tartalmazó nnklelnsav, e) a SEQ ID No. 41 szerinti nehézSáno-SKekveneíát ós a SiQ XD No, 44 szerinti kSnnyáláae-szekvencíát íariai-mazó DNS-szekvenriát tartalmazó nukleínsay, d) a. hj és/vagy c) pontban· meghatázozottiöuisléíhsaváksák megfelelő RNS óókleisssvak, és e) az a), b) és c) pontban meghaiározott tttilMfes&amp;vzkkal komplementer mtkletnsavak. lő. Meteor, amely $. igésypotti szerinti aakleinsayat tedahn&amp;z,
  5. 11. Qszdasejt, amely 10. igénypont szerinti vektort tartalmaz.
  6. 12. Kijárás L, 2. és 4-8. igénypontok bármelyike sjéenhtí elíemmyag vágy égy s-Meket kötö (lívafcös fiagrneßse előállítására, azzal jéllemszve, hogy az eljárás magába» foglalja aMvetlmzöket. aj 11. igénypont szériái gimdasOji: tenyésztés® tenytpsztőközegbe» és megjelelő íönyészMmknétiyek közölt, és 0) .stz eileoartyag vagy egv c-Met-et kótö dlváleos áapöeose kinyerése a ienyészközegböi: vagy a tenyésztőit sejtekből
  7. 13. Az 1., 2. és 4-8. igénypontok öársnelyíke szednü eiiénaeyag vagy egy e-Méh-eí kotö díVakms: íragmense vagy a 12. igénypont szedni eljárással előállított ellenanyag vagy egy c-Met-et köíö dtvalens íragmense, gyógyszerként történő alkalmazásra,
  8. 14. Készítmény, amely hatóanyagként L, f. és 4-8. Igénypontok bármelyiké szerinti: Vágy 12. igénypont szerint, eljárással előállított vagy 3.·. igénypont szerinti híbrtdáma. által termelt ellenanyag vagy égy é-Met-et kötő aktivitása divalehs íragmense alkotta. vegyöleíet tartalmaz. 15. A 14. igénypont szerími készítmény, azzal jellemezve, hogy tartalmaz továbbá egyidejű, elkülönített vagy egyatást kővető alkalmazásra kombináeiős termékként egy hatóanyagot, ahöl a hatóanyag aaÉtanor elten-anyag. l é, À 14, vagy 15. igénypont szedelí: készitnréay, azzal jellemezve, hogy tartalmaz továbbá egy táéja:, elkülönített vágy egytbást kővető alkalmazást» kombi:oáeiös termékként: legalább egy hatóanyagot,: ahol a ható* anyag eitotoxíkns/ciíosztatikus hatóanyag. 0. A 14-11;: igéiiÿpôtiiok bármelyiké szerinti Mszítínény, áösal jeUéîhezvè, hogy az éllehahpgofc: vagy e-Mébét kötö díyáléns fragthénsesk legalább egyike sejttoxipnal ésévagv raóíoeiermhél konjngátt, 1:8. A 14-17, igénypontok bármelyike szerinti készítmény gyógyszerként történd alkalmazásra. If. Az 1., 2. és 4-8. igéns^poníok bármelyike szerinti .'vagy 12. igénypont szerint eljárással előállított vagy 3. igénypont szerinti hibridéma által termeli ellenanyag vagy egy o-Met-et kötő divtfers Sagarense vagy a 14* 1?, Igénypontok bármelyike szerinti készitmétry alkáhsazása rák megelőzésére Vagy kezelésére szolgáló gyógyszer előállítására, 2d . A 19. Igénypont szeríhtl alkalmazás, ázzál jéllémezve, hogy a rák a Mveílezők közöl választott rák: prosztatarák, oszteoszarkötnák, iilöórSk, mellrák, egáömetdáls sgk, gMoMasztoma vagy vasíagbéMk, íil. A if. vagy 20. igptiypont szerinti alkalmazás, ázzál jellemezve, hogy a rák s-Mel-aktivádéval: össze-hlggö sik., amely MGF-íbggö és/vagy -Siggetien rák közül választott. :22, Bljásys a p*Met receptor tokozott expressziója vagy csökkent expressziója állat indukált béíegsógek ín víbO iíagmisztízálását'a olyan biológiai mintából kiindulva, amelyben orMet recopiiez aheormáíiS jelenléte Mtéiélézékí stzzsd jellemezve, hogy az eljárás: magában íoglajja a kővetkező lépést: a hiolégiél minta értnikez-tetéseAZ: és 4-8. igénypontok bármelyike szerfató vagy a 12. igénypont: szerinti eljárássá! élMliítoít vagy a 3. igénypont perínti: hibrklómá: áltál termelt dlenanyaggat: vagy egy o-ÍVíet-et köíó chvaieas Éagmensével, ahol, amermyiben szükséges, lehetséges az ellenanyag jelölése.
HUE08786050A 2007-07-12 2008-07-10 Új, C-met-dimerizációt gátló ellenanyagok és alkalmazásuk HUE026026T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (en) 2007-07-12 2007-07-12 Novel antibodies inhibiting c-met dimerization, and uses thereof
US2063908P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
HUE026026T2 true HUE026026T2 (hu) 2016-05-30

Family

ID=38871713

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08786050A HUE026026T2 (hu) 2007-07-12 2008-07-10 Új, C-met-dimerizációt gátló ellenanyagok és alkalmazásuk

Country Status (36)

Country Link
US (6) US8329173B2 (hu)
EP (6) EP2014681A1 (hu)
JP (4) JP5562844B2 (hu)
KR (4) KR101719084B1 (hu)
CN (4) CN101981054B (hu)
AR (4) AR067517A1 (hu)
AU (1) AU2008274171B2 (hu)
BR (1) BRPI0815564B8 (hu)
CA (4) CA2888691C (hu)
CL (1) CL2008002015A1 (hu)
CO (1) CO6170364A2 (hu)
CY (1) CY1116608T1 (hu)
DK (1) DK2188312T3 (hu)
ES (5) ES2693542T3 (hu)
HK (3) HK1149024A1 (hu)
HR (1) HRP20150887T1 (hu)
HU (1) HUE026026T2 (hu)
IL (5) IL203114A (hu)
MA (1) MA31977B1 (hu)
ME (1) ME02341B (hu)
MX (3) MX345391B (hu)
MY (1) MY158756A (hu)
NZ (4) NZ613716A (hu)
PA (1) PA8789201A1 (hu)
PH (3) PH12018502040A1 (hu)
PL (1) PL2188312T3 (hu)
PT (1) PT2188312E (hu)
RS (1) RS54197B1 (hu)
RU (1) RU2552161C2 (hu)
SA (1) SA08290423B1 (hu)
SG (1) SG183015A1 (hu)
SI (1) SI2188312T1 (hu)
TN (1) TN2010000016A1 (hu)
TW (4) TWI592427B (hu)
WO (1) WO2009007427A2 (hu)
ZA (1) ZA201000966B (hu)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (en) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US9469691B2 (en) * 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
CN107739407B (zh) * 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
EP2576622A4 (en) * 2010-06-01 2013-11-27 Univ Monash ANTIBODIES AGAINST RECEPTOR TYROSINE KINASE C-MET
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP3264089A1 (en) 2010-08-31 2018-01-03 Genentech, Inc. Biomarkers and methods of treatment
JP5955322B2 (ja) * 2010-09-03 2016-07-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃ−ｍｅｔ抗体及びその使用方法
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2594493T3 (es) * 2010-11-03 2016-12-20 arGEN-X BV Anticuerpos anti-c-Met
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
KR101444837B1 (ko) * 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4218933A1 (en) * 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
WO2013043715A1 (en) 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CA2850261C (en) * 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
JP2014533700A (ja) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
US9376485B2 (en) 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP5614733B2 (ja) * 2012-09-05 2014-10-29 Jsr株式会社 細胞の上皮性維持に作用する物質のスクリーニング方法
RS58921B1 (sr) 2012-10-12 2019-08-30 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
EP2964676A1 (en) 2013-03-06 2016-01-13 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
WO2015031614A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
WO2016053610A1 (en) * 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
CN107002133B (zh) * 2014-11-20 2022-07-05 天主教大学基金会 Met的新型自活化且细胞内的突变体
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
CA2981398A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
WO2017062496A2 (en) * 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
CN108350078A (zh) 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
IL294146B2 (en) 2016-05-17 2024-01-01 Abbvie Biotherapeutics Inc Antibody conjugates against cMet with a drug and methods of using them
US11427632B2 (en) * 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2019018538A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. RECOMBINANT ANTIBODIES BINDING TO CD123
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
WO2019117691A1 (ko) * 2017-12-15 2019-06-20 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
CN116874591A (zh) * 2018-03-24 2023-10-13 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116783220A (zh) * 2020-12-16 2023-09-19 武汉友芝友生物制药股份有限公司 抗bcma抗体及其制备方法和应用
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023129928A2 (en) * 2021-12-27 2023-07-06 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
EP0970126B1 (en) * 1997-04-14 2001-04-18 Micromet AG Novel method for the production of antihuman antigen receptors and uses thereof
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1476120B1 (en) * 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
ZA200701656B (en) * 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
US8080638B2 (en) * 2005-02-10 2011-12-20 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
NZ625807A (en) 2005-07-18 2015-11-27 Amgen Inc Human anti-b7rp1 neutralizing antibodies
EP1913027B1 (en) 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
WO2007090807A1 (en) 2006-02-06 2007-08-16 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)

Also Published As

Publication number Publication date
ME02341B (me) 2015-12-31
US8871909B2 (en) 2014-10-28
BRPI0815564B1 (pt) 2020-01-21
CA2982484A1 (en) 2009-01-15
AR109659A2 (es) 2019-01-09
US8329173B2 (en) 2012-12-11
NZ583041A (en) 2012-06-29
HK1149024A1 (en) 2011-09-23
KR20100044212A (ko) 2010-04-29
CA2694418C (en) 2018-03-27
TW201605892A (zh) 2016-02-16
JP5889925B2 (ja) 2016-03-22
EP2415784B1 (en) 2018-06-13
CA2982484C (en) 2021-06-01
EP2188312A2 (en) 2010-05-26
CA2888691C (en) 2023-01-03
TW201437231A (zh) 2014-10-01
JP2010532982A (ja) 2010-10-21
US20150252114A1 (en) 2015-09-10
US20130273060A1 (en) 2013-10-17
AR109660A2 (es) 2019-01-09
JP2014113154A (ja) 2014-06-26
AR109535A2 (es) 2018-12-19
HK1193619A1 (zh) 2014-09-26
US9107907B2 (en) 2015-08-18
TW201605891A (zh) 2016-02-16
HK1193620A1 (zh) 2014-09-26
TN2010000016A1 (en) 2011-09-26
CN103183739B (zh) 2016-08-17
ZA201000966B (en) 2011-02-23
RS54197B1 (en) 2015-12-31
CN103509112B (zh) 2015-10-21
CN103509113B (zh) 2015-10-21
KR20150070451A (ko) 2015-06-24
MA31977B1 (fr) 2011-01-03
WO2009007427A2 (en) 2009-01-15
MX353449B (es) 2018-01-08
ES2678495T3 (es) 2018-08-13
IL223106B (en) 2020-06-30
NZ613716A (en) 2015-01-30
WO2009007427A3 (en) 2009-04-09
CA2888691A1 (en) 2009-01-15
US8889832B2 (en) 2014-11-18
EP2535356A1 (en) 2012-12-19
CA2981821A1 (en) 2009-01-15
JP5889924B2 (ja) 2016-03-22
PH12018502039A1 (en) 2019-08-19
EP2535356B1 (en) 2018-06-13
CN103509112A (zh) 2014-01-15
TW200911828A (en) 2009-03-16
IL223109B (en) 2019-06-30
TWI592427B (zh) 2017-07-21
US20130272957A1 (en) 2013-10-17
PA8789201A1 (es) 2009-08-26
IL223105A0 (en) 2012-12-31
IL223108B (en) 2019-06-30
IL223106A0 (en) 2012-12-31
HRP20150887T1 (hr) 2015-09-25
MY158756A (en) 2016-11-15
CA2981821C (en) 2020-07-28
CA2694418A1 (en) 2009-01-15
JP2014113155A (ja) 2014-06-26
SG183015A1 (en) 2012-08-30
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
CN103183739A (zh) 2013-07-03
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
KR101701686B1 (ko) 2017-02-01
IL203114A (en) 2015-03-31
EP2415784A1 (en) 2012-02-08
NZ599958A (en) 2013-11-29
AU2008274171B2 (en) 2014-02-27
EP2188312B1 (en) 2015-05-27
CN101981054B (zh) 2015-04-15
EP2415785B1 (en) 2018-04-25
EP2014681A1 (en) 2009-01-14
IL223108A0 (en) 2012-12-31
KR101625234B1 (ko) 2016-05-30
US20100115639A1 (en) 2010-05-06
EP2535357A1 (en) 2012-12-19
RU2552161C2 (ru) 2015-06-10
SA08290423B1 (ar) 2013-12-23
AU2008274171A1 (en) 2009-01-15
PT2188312E (pt) 2015-10-05
KR101701685B1 (ko) 2017-02-01
US20130280257A1 (en) 2013-10-24
JP5562844B2 (ja) 2014-07-30
SI2188312T1 (sl) 2015-09-30
JP2014113153A (ja) 2014-06-26
CY1116608T1 (el) 2017-03-15
PH12018502038A1 (en) 2019-08-19
ES2693542T3 (es) 2018-12-12
CN103509113A (zh) 2014-01-15
DK2188312T3 (en) 2015-08-03
US20140010818A1 (en) 2014-01-09
AR067517A1 (es) 2009-10-14
IL223109A0 (en) 2012-12-31
TWI602829B (zh) 2017-10-21
PL2188312T3 (pl) 2016-01-29
KR101719084B1 (ko) 2017-03-22
MX341012B (es) 2016-08-03
BRPI0815564A2 (pt) 2015-02-18
CL2008002015A1 (es) 2008-11-21
RU2010104633A (ru) 2011-08-20
PH12018502040A1 (en) 2019-08-19
ES2686693T3 (es) 2018-10-19
MX345391B (es) 2017-01-27
US8871910B2 (en) 2014-10-28
EP2535357B1 (en) 2018-08-08
TWI602830B (zh) 2017-10-21
KR20160019974A (ko) 2016-02-22
CO6170364A2 (es) 2010-06-18
IL223105B (en) 2020-02-27
JP5889923B2 (ja) 2016-03-22
TWI549965B (zh) 2016-09-21
BRPI0815564B8 (pt) 2021-05-25
CN101981054A (zh) 2011-02-23
EP2415785A1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
DK2188312T3 (en) Hitherto UNKNOWN ANTIBODIES INHIBITING C-MET DIMERIZATION AND APPLICATIONS THEREOF
AU2016228280B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2014200630B2 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof